This is, of course, just a continuation of the one awarded about a month ago. It'd be handy if filers were required to bold the different stuff. I can dream.
Edit: In this new version, there some different numbers in claim #4, and there is no claim #8.
Press Release Source: Savient Pharmaceuticals, Inc. On Monday October 25, 2010, 11:33 am
EAST BRUNSWICK, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq:SVNT - News) today announced that its previously announced process to identify, following the approval of KRYSTEXXA™ by the U.S. Food and Drug Administration (FDA), a strategic transaction for the sale of the Company did not result in a sale of the Company at this time. The board of directors will continue to evaluate strategic alternatives available to the Company to maximize value.
The Company is working toward the commercial launch of KRYSTEXXA, which it expects will be available by prescription in the U.S. later this year. The Company will host a conference call on Tuesday, October 26, 2010, at 8:30 a.m. during which it will provide further detail around its launch plans.
Conference Call Information
Savient's management team will host a live conference call and webcast on October 26, 2010 at 8:30 a.m. Eastern Time. Call-in information will be provided in a separate press release shortly.
Market Data 
Markets 
AI
